New York- and London-based HealthTech venture firm Eckuity has invested in Mobius Biomedical, a development-stage company designing disruptive new technology and processes for lower cost, next-generation biologics manufacturing.
Mobius Biomedical’s disruptive technology will significantly reduce facility footprint, setup time, and cost, while at the same time providing the flexibility to manufacture a diverse set of biological drug products, as its flexible equipment modules are designed to enable continuous manufacturing of protein-therapeutics, RNA-therapeutics, and gene therapies. Mobius’ technologies will provide reductions in manufacturing cost and time to market, while simultaneously improving product yield and purity.
